Like the third runner-up in the game, Hepatitis C did not have an exclusive name, and it has long been called non-A, non-B hepatitis virus. It was not until 1989 that researchers successfully separated them through a new molecular biotechnology, and that they had a formal name. Until today, their awareness rate is still not comparable to that of hepatitis B.

Infected with hepatitis C virus, most of the patients have no obvious symptoms. When they are discovered, they are often more than ten years old, and even decades later, they may have reached the stage of liver cirrhosis and even liver cancer. Hepatitis C is therefore called the “invisible killer” by the industry, and it is also the infectious disease that causes cancer and causes death after the second meeting of hepatitis B.

According to the World Health Organization (WHO), about 180 million people worldwide are infected with hepatitis C virus (HCV), with 35,000 new cases each year. In fact, because the public can not understand the hepatitis C, and the rate of missed diagnosis of hepatitis C virus is high, nearly 80% of patients do not know that they have hepatitis C, and even more serious.

Continue to strengthen the voice of hepatitis C science

The Fifth Medical Center of the People's Liberation Army General Hospital (formerly 302 Hospital) Director Chen Guofeng of the Second Division of Liver Cirrhosis believes that “usually some sudden, globally ill, and more serious diseases, especially infectious diseases, will be called global. Public health problems. According to the current number of hepatitis C patients, hepatitis C is a global public health problem. The prevention and treatment of such problems is enough to attract the attention of global institutions and governments. For example, the goal of WHO is to eliminate hepatitis C in 2030. China also updated the guidelines for prevention and treatment of hepatitis C in 2015. Although significant progress has been made, it is necessary to increase the intensity of screening for high-risk groups and try to be as good as possible.

"Like hepatitis B, hepatitis C transmission is mainly blood transmission, sexual transmission and mother-to-child transmission. Because our awareness of hepatitis C is not high, the current discovery of hepatitis C has obvious contingency, and patients often have dental bleeding or necessary preoperative examination. Blood donation, pre-production inspection was discovered. In view of a transmission route of hepatitis C, it is recommended that high-risk groups such as drug users, sex workers, and AIDS patients actively take hepatitis C check. If the general population has been exposed to the route of transmission, they must also arrive in time. The hospital conducts inspections, such as washing teeth, eyebrows, acupuncture, etc. in clinics with less strict disinfection, and even more sexual partners or unclean sex.” Director Chen Guofeng also said, “In the current social environment, each A medical beauty project is popular, but there may be risks. Although the state's supervision of such institutions is becoming more and more strict, it is not excluded that some institutions will still operate in strict accordance with the norms due to reasons such as cost considerations, such as Use non-disposable syringes, needles, and needles or intrusions using items that are not strictly sterilized Operation.

Director Chen Guofeng believes that a very clear goal of hepatitis C science is to enable high-risk groups to do 100% inspections. If necessary, the hepatitis C examination should be included in the company's annual medical examination program, which can help patients with hepatitis C to find early treatment as soon as possible. Protect the children of the family members of the patient knowingly. However, in the case of public awareness of hepatitis C is not comprehensive, the unified inspection of hepatitis C requires enterprises to do a good job of employee privacy protection.

What should I do after exposure to the high-risk transmission path of hepatitis C?

Director Chen Guofeng said, “After infection with hepatitis C virus, 15%-35% of people can self-removal and self-healing because of individual differences. However, most patients will become chronically infected, and it is recommended to contact groups after high-risk transmission. Being able to go to the hospital for targeted inspections in time."

Like AIDS, hepatitis C virus does not produce antibodies immediately after infection. It takes 4-24 weeks to detect anti-HCV (hepatitis C virus antibodies) from serum. HCV RNA (hepatitis C virus RNA) appears earlier and takes 2 weeks. The time around. This means that after a high-risk exposure, it takes two to four weeks to check. If you donate blood in the "window period", it is likely that missed detection of anti-HCV and HCV RNA in the blood may result in missed treatment and a spread of hepatitis C virus.

What is the current diagnosis and treatment of hepatitis C?

When the virus attacks the body, antibodies are produced, but the hepatitis C virus antibody cannot fight and eliminate the hepatitis C virus, and it cannot protect the body. Despite this, the diagnosis of hepatitis C is primarily an antibody, and if it is negative, it does not require treatment. If it is positive, it indicates that it has been infected with hepatitis C virus or has been infected with hepatitis C virus, so anti-HCV test is generally used as a preliminary screening test for hepatitis C.

To further understand the condition of the virus, HCV-RNA detection is required. If it is negative, there is no need to treat it. If it is positive, regardless of the level of transaminase, the corresponding treatment should be carried out. The diagnosis of hepatitis B is different. If the hepatitis B virus is positive, but the transaminase is normal, the patient may be a carrier of hepatitis B virus and may not be treated.

Hepatitis C virus has rapid mutations and many subtypes. It is precisely because of this feature that hepatitis C vaccine has not yet been developed, and it is impossible to prevent it by vaccination like hepatitis B.

In terms of specific treatment, Director Chen Guofeng told us that the treatment of hepatitis C has gone through a long process. Early hepatitis C treatment mainly uses a single interferon method. Interferon is a factor produced by lymphocytes under the stimulation of viruses in the human immune system. It can only interfere with viral replication by increasing human immune function, and does not directly kill or inhibit the virus. Therefore, the cure rate is low and the side effects are obvious. At present, there are three kinds of interferons commonly used in clinical practice: pegylated interferon α-2a, pegylated interferon α-2b and common interferon. The first two are long-acting interferons, once a week, followed by One is a short-acting interferon that needs to be injected once every other day.

The combination of ribavirin and interferon has significantly improved the cure rate of hepatitis C. It can be said that before 2013, the combination of interferon and ribavirin has always been the main treatment for hepatitis C. However, because the two are not highly targeted to hepatitis C virus, the combination of interferon and ribavirin is not ideal, and some serious side effects caused many patients to give up treatment. A 2011 study of 997 cases of hepatitis C in China showed that more than 50% of people infected with hepatitis C virus were unsuitable or unable to tolerate treatment with interferon plus ribavirin.

Of course, medical researchers have been developing more effective antiviral drugs. In 2011, the first generation of Direct-acting Antiviral Agent (DAA) was introduced, which significantly improved the virus clearance rate of hepatitis C. In 2013, the birth of sophos-Bubwe brought new hope to patients with hepatitis C. By blocking the hepatitis C virus protein NS5B, it completely cut off the process of viral replication and assembly, and the cure rate of hepatitis C reached 95%. Sophorabine can play a role in the chronic hepatitis C of the six genotypes and can cover the widest range of patients.

But sophos-Bubwe does not solve all the problems. Hepatitis C virus non-structural proteins are the main components of viral replication. In addition to NSB proteins, there are several other key proteins, such as NS5A and NS3/4A. This also makes it impossible to cure patients with sophos-blister alone, or to still need interferon or other DAA drugs. After 2014, the treatment of hepatitis C does not require interferon, achieving the goal of curing oral hepatitis D with all oral DAA drugs. Gilead has followed up and developed a joint preparation that can simultaneously block NS5A protein, which is commonly known as "Jijidai" Havani and "Jisan" Bingtongsha, and the "Ji Si" that was approved by the US FDA in 2017. Generation" Vosevi.

As the first pan-genotype of hepatitis C treatment, Bentongsha was approved by the State Drug Administration on May 23, 2018 for the treatment of adult infected patients with genotype 1-6 chronic hepatitis C virus (HCV).

In this regard, Director Chen Guofeng said that the pan-gene antiviral efficacy of Bentongsha is obvious to all. In the specific treatment, it is not necessary to constantly monitor, which saves the patient's funds and saves the time of patients and doctors. But specific to a certain genotype, there can be multiple DAA drug treatment options to choose from, and Bentongsha should be one of the best treatment options. In the future, hepatitis C treatment still has a lot of room for improvement. At the same time, it is not excluded that the hepatitis C vaccine will be successfully developed.

When talking about the value of Internet medical care in the entire medical system, Director Chen Guofeng believes that the value of Internet medical care is very obvious, especially in patient management, as well as electronic prescription and drug delivery. At present, the Medical Association has reached a strategic cooperation with Gilead. In the case of hepatitis C single disease, the online and offline medical treatment will form a closed loop, which will bring convenience to patients.

Director Chen Guofeng told us that the general patient can be cured by using a course of Bentham. Compared with the traditional combination therapy of ribavirin and interferon, Bunda sand has a short cycle, high safety and low side effects.

Despite this, because the economic situation of patients with hepatitis C is different, the inclusion of medical insurance is still an urgent demand of most patients with hepatitis C. The national medical insurance department shoulders the mission of “killing the price” for the people. Just after the establishment, 17 anticancer drugs were included in the national medical insurance catalogue through negotiations, with an average reduction of 56.7%, the largest drop of 71%, and the payment of most imported drugs after negotiation. The standard is lower than the market price of neighboring countries or regions, with an average lower 36%.

China is a country with a large population, and the number of hepatitis C patients is the largest in the world. If Bentongsha enters China's medical insurance, it means a broader market. The data shows that the five countries in Europe (Italy, France, Spain, Germany, the United Kingdom) have raised the national productivity of hepatitis C by as much as 2.7 billion euros. For China, the inclusion of Bentongsha in medical insurance means that more and more hepatitis C patients are easily cured, which means higher national productivity.

Vault Room

Vault Room Construction,Vault Room In House,Vault Room Door,Vault Room

Hebei Yingbo Safe Boxes Co.,Ltd , https://www.ybsafebox.com